Collaborations & Alliances

GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate 

Will jointly support preclinical development activities for GNX201-ADC for the treatment of solid tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GlycoNex, Inc. (GNX), a clinical-stage biotechnology company focused on glycan-directed cancer immunotherapies, has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. to advance GNX201-ADC, a next-gen antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. The companies will jointly support preclinical development activities for GNX201-ADC, leveraging their respective expertise in antibody engineering and oncology drug development. The collaboration will ce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters